CONTACT: Tierney Saccavino (914) 326-5104 tsaccavino@acorda.com FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Third Quarter 2023 Financial Results • INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4$15.7 million; 26% decrease over Q3 2022 • INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of$2.5 million • Biopas Laboratories files for approval of INBRIJA in six Latin American countries PEA ...